Public trust is the key to unlocking the full potential of the bioeconomy. Without it, the U.S. may fall short of long-term economic goals and biotech leadership.
Despite significant advances in scientific tools and methods, the traditional, labor-intensive model of scientific research in materials discovery has seen little innovation.
We’ve created a living table to track progress on the Bioeconomy EO, enhance accountability, and follow the state of the U.S. bio economy as it evolves.
Read FAS Senior Policy Fellow Jennifer Pahlka’s testimony on Harnessing AI to Improve Government Services and Customer Experience here.
Five federal policy recommendations to maximize opportunity and minimize risk at the intersection of biology and artificial intelligence
The landscape of biosecurity risks related to AI is complex and rapidly changing, and understanding the range of issues requires diverse perspectives and expertise. Here are five promising ideas that match the diversity of challenges that AI poses in the life sciences.
Excited delirium, a diagnosis generally characterized by a severely agitated state, made headlines in some of the most contentious deaths in custody.
Common frameworks for evaluating proposals leave this utility function implicit, often evaluating aspects of risk, uncertainty, and potential value independently and qualitatively.
As Congress moves forward with the appropriations process, both the House and Senate have proposed various provisions related to artificial intelligence (AI) and machine learning (ML) across different spending bills.
The looming competition for global talent has brought forth a necessity to evaluate and update the policies concerning international visa holders in the United States.
Researchers at the nonpartisan science think tank support Biden’s executive order on the use of artificial intelligence in government.
Successful commercialization efforts have now grown across the country, but what do they have in common, and why do they work? Our experts weigh in.